Lombard Odier Asset Management Europe Ltd Has $1.73 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Lombard Odier Asset Management Europe Ltd trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 38.0% in the first quarter, according to its most recent filing with the SEC. The firm owned 12,396 shares of the biopharmaceutical company’s stock after selling 7,604 shares during the period. Lombard Odier Asset Management Europe Ltd’s holdings in Gilead Sciences were worth $1,728,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in GILD. Paulson Wealth Management Inc. raised its position in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 67 shares in the last quarter. Essex Financial Services Inc. boosted its holdings in Gilead Sciences by 0.9% during the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares in the last quarter. Davidson Trust Co. grew its stake in shares of Gilead Sciences by 4.1% in the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after purchasing an additional 74 shares during the period. Alpha Cubed Investments LLC grew its stake in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after purchasing an additional 75 shares during the period. Finally, Personal CFO Solutions LLC raised its holdings in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 76 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $131.15 on Tuesday. The stock has a market capitalization of $162.83 billion, a P/E ratio of 17.87 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 1 year low of $108.46 and a 1 year high of $157.29. The firm has a 50 day moving average of $129.55 and a 200-day moving average of $136.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period in the prior year, the company earned $1.81 EPS. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Analyst Ratings Changes

GILD has been the subject of several analyst reports. Royal Bank Of Canada cut their target price on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Daiwa Securities Group lowered their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Truist Financial dropped their price objective on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Morgan Stanley cut their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. Finally, Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Twenty-five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $157.93.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares in the company, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 67,000 shares of company stock valued at $8,687,140. 0.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.